Relationship of Oxidized Phospholipids and Biomarkers of Oxidized Low-Density Lipoprotein With Cardiovascular Risk Factors, Inflammatory Biomarkers, and Effect of Statin Therapy in Patients With Acute Coronary Syndromes. Results From the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) Trial

Journal of the American College of Cardiology

Volumn 53, Issue 23, 2009, Pages 2186-2196

  Fraley, Alexander E ^a   Schwartz, Gregory G ^b   Olsson, Anders G ^c   Kinlay, Scott ^d,f   Szarek, Michael ^e   Rifai, Nader ^g   Libby, Peter ^f   Ganz, Peter ^f,h   Witztum, Joseph L ^a   Tsimikas, Sotirios ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c LINKÖPING UNIVERSITY   (Sweden)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e PFIZER INC   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g BOSTON CHILDREN S HOSPITAL   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

acute coronary syndromes; lipoproteins; oxidation; risk factors; statins

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN B100; ATORVASTATIN; C REACTIVE PROTEIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; INTERLEUKIN 6; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; OXIDIZED LOW DENSITY LIPOPROTEIN; PADGEM PROTEIN; PLACEBO; SERUM AMYLOID A; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE MARKER; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEART INFARCTION; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOSIS; UNSTABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; AGED; AGED, 80 AND OVER; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEINS B; AUTOANTIBODIES; BIOLOGICAL MARKERS; CHOLESTEROL, LDL; COHORT STUDIES; FEMALE; HEPTANOIC ACIDS; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFLAMMATION; LIPOPROTEIN(A); MALE; MIDDLE AGED; OXIDATION-REDUCTION; PHOSPHOLIPIDS; PYRROLES; REACTIVE OXYGEN SPECIES; RISK FACTORS; THROMBOEMBOLISM;

EID: 66149131879     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2009.02.041     Document Type: Article

References (46)

1. Schwartz G.G., Olsson A.G., Ezekowitz M.D., et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285 (2001) 1711-1718
2. Waters D.D., Schwartz G.G., Olsson A.G., et al. Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy. Circulation 106 (2002) 1690-1695
3. Tsimikas S., Witztum J.L., Miller E.R., et al. High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial. Circulation 110 (2004) 1406-1412
4. Bergmark C., Dewan A., Orsoni A., et al. A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma. J Lipid Res 49 (2008) 2230-2239
5. Edelstein C., Pfaffinger D., Hinman J., et al. Lysine-phosphatidylcholine adducts in kringle V impart unique immunological and potential pro-inflammatory properties to human apolipoprotein(a). J Biol Chem 278 (2003) 52841-52847
6. Tsimikas S., Bergmark C., Beyer R.W., et al. Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. J Am Coll Cardiol 41 (2003) 360-370
7. Tsimikas S., Brilakis E.S., Miller E.R., et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med 353 (2005) 46-57
8. Tsimikas S., Kiechl S., Willeit J., et al. Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: five-year prospective results from the Bruneck study. J Am Coll Cardiol 47 (2006) 2219-2228
9. Silaste M.L., Rantala M., Alfthan G., et al. Changes in dietary fat intake alter plasma levels of oxidized low-density lipoprotein and lipoprotein(a). Arterioscler Thromb Vasc Biol 24 (2004) 498-503
10. Rodenburg J., Vissers M.N., Wiegman A., et al. Oxidized low-density lipoprotein in children with familial hypercholesterolemia and unaffected siblings: effect of pravastatin. J Am Coll Cardiol 47 (2006) 1803-1810
11. Ky B., Burke A., Tsimikas S., et al. The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans. J Am Coll Cardiol 51 (2008) 1653-1662
12. Choi S.H., Chae A., Miller E., et al. Relationship between biomarkers of oxidized low-density lipoprotein, statin therapy, quantitative coronary angiography, and atheroma: volume observations from the REVERSAL (Reversal of Atherosclerosis with Aggressive Lipid Lowering) study. J Am Coll Cardiol 52 (2008) 24-32
13. Tsimikas S., Aikawa M., Miller Jr. F.J., et al. Increased plasma oxidized phospholipid:apolipoprotein B-100 ratio with concomitant depletion of oxidized phospholipids from atherosclerotic lesions after dietary lipid-lowering: a potential biomarker of early atherosclerosis regression. Arterioscler Thromb Vasc Biol 27 (2007) 175-181
14. Itabe H., and Ueda M. Measurement of plasma oxidized low-density lipoprotein and its clinical implications. J Atheroscler Thromb 14 (2007) 1-11
15. Holvoet P., Harris T.B., Tracy R.P., et al. Association of high coronary heart disease risk status with circulating oxidized LDL in the well-functioning elderly: findings from the Health, Aging, and Body Composition study. Arterioscler Thromb Vasc Biol 23 (2003) 1444-1448
16. Fraley A.E., and Tsimikas S. Clinical applications of circulating oxidized low-density lipoprotein biomarkers in cardiovascular disease. Curr Opin Lipidol 17 (2006) 502-509
17. Tsimikas S. In vivo markers of oxidative stress and therapeutic interventions. Am J Cardiol 101 (2008) 34D-42D
18. Kinlay S., Schwartz G.G., Olsson A.G., et al. Inflammation, statin therapy, and risk of stroke after an acute coronary syndrome in the MIRACL study. Arterioscler Thromb Vasc Biol 28 (2008) 142-147
19. Aikawa M., Sugiyama S., Hill C.C., et al. Lipid lowering reduces oxidative stress and endothelial cell activation in rabbit atheroma. Circulation 106 (2002) 1390-1396
20. Torzewski M., Shaw P.X., Han K.R., et al. Reduced in vivo aortic uptake of radiolabeled oxidation-specific antibodies reflects changes in plaque composition consistent with plaque stabilization. Arterioscler Thromb Vasc Biol 24 (2004) 2307-2312
21. Crisby M., Nordin-Fredriksson G., Shah P.K., Yano J., Zhu J., and Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 103 (2001) 926-933
22. Tsimikas S., and Witztum J.L. The role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity. Curr Opin Lipidol 19 (2008) 369-377
23. Briley-Saebo K.C., Shaw P.X., Mulder W.J., et al. Targeted molecular probes for imaging atherosclerotic lesions with magnetic resonance using antibodies that recognize oxidation-specific epitopes. Circulation 117 (2008) 3206-3215
24. Kiechl S., Willeit J., Mayr M., et al. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study. Arterioscler Thromb Vasc Biol 27 (2007) 1788-1795
25. Tsimikas S., Mallat Z., Talmud P.J., et al. Elevated oxidized phospholipids on apolipoprotein B-100 particles are associated with future cardiovascular events in the EPIC-Norfolk study: potentiation of risk with lipoprotein-associated (Lp-PLA2) and secretory phospholipase A2 (sPLA2) activity (abstr). Circulation 118 Suppl 2 (2008) S1128
26. Binder C.J., Shaw P.X., Chang M.K., et al. The role of natural antibodies in atherogenesis. J Lipid Res 46 (2005) 1353-1363
27. Shoenfeld Y., Wu R., Dearing L.D., and Matsuura E. Are anti-oxidized low-density lipoprotein antibodies pathogenic or protective?. Circulation 110 (2004) 2552-2558
28. Tsimikas S., Clopton P., Brilakis E.S., et al. Relationship of oxidized phospholipids on apolipoprotein B-100 particles to race/ethnicity, apolipoprotein(a) isoform size, and cardiovascular risk factors: results from the Dallas Heart Study. Circulation 119 (2009) 1711-1719
29. Palinski W., Rosenfeld M.E., Ylä-Herttuala S., et al. Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci U S A 86 (1989) 1372-1376
30. Ylä-Herttuala S., Palinski W., Rosenfeld M.E., et al. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest 84 (1989) 1086-1095
31. Palinski W., Ylä-Herttuala S., Rosenfeld M.E., et al. Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. Arteriosclerosis 10 (1990) 325-335
32. Salonen J.T., Korpela H., Salonen R., et al. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 339 (1992) 883-887
33. Ylä-Herttuala S., Palinski W., Butler S.W., Picard S., Steinberg D., and Witztum J.L. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler Thromb 14 (1994) 32-40
34. Mayr M., Kiechl S., Tsimikas S., et al. Oxidized low-density lipoprotein autoantibodies, chronic infections, and carotid atherosclerosis in a population-based study. J Am Coll Cardiol 47 (2006) 2436-2443
35. Fredrikson G.N., Hedblad B., Berglund G., et al. Association between IgM against an aldehyde-modified peptide in apolipoprotein B-100 and progression of carotid disease. Stroke 38 (2007) 1495-1500
36. Wilson P.W.F., Ben Yehuda O., McNamara J., Massaro J., Witztum J.L., and Reaven P.D. Autoantibodies to oxidized LDL and cardiovascular risk: the Framingham Offspring study. Atherosclerosis 189 (2006) 364-368
37. Iughetti L., Volta C., Maggi E., et al. Circulating antibodies recognizing oxidatively modified low-density lipoprotein in children. Pediatr Res 45 (1999) 94-99
38. Tinahones F.J., Mez-Zumaquero J.M., Rojo M., et al. Increased levels of anti-oxidized low-density lipoprotein antibodies are associated with reduced levels of cholesterol in the general population. Metabolism 51 (2002) 429-431
39. Steinerova A., Stozicky F., Racek J., Tatzber F., Zima T., and Setina R. Antibodies against oxidized LDL in infants. Clin Chem 47 (2001) 1137-1138
40. Tsimikas S., Brilakis E.S., Lennon R.J., et al. Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events. J Lipid Res 48 (2007) 425-433
41. 2 and the effect of atorvastatin treatment. Atherosclerosis 196 (2008) 289-297
42. Orem C., Orem A., Uydu H.A., Celik S., Erdol C., and Kural B.V. The effects of lipid-lowering therapy on low-density lipoprotein auto-antibodies: relationship with low-density lipoprotein oxidation and plasma total antioxidant status. Coron Artery Dis 13 (2002) 65-71
43. Fredrikson G.N., Schiopu A., Berglund G., Alm R., Shah P.K., and Nilsson J. Autoantibody against the amino acid sequence 661-680 in apo B-100 is associated with decreased carotid stenosis and cardiovascular events. Atherosclerosis 194 (2007) e188-e192
44. Resch U., Tatzber F., Budinsky A., and Sinzinger H. Reduction of oxidative stress and modulation of autoantibodies against modified low-density lipoprotein after rosuvastatin therapy. Br J Clin Pharmacol 61 (2006) 262-274
45. Schumacher M., Eber B., Tatzber F., et al. Transient reduction of autoantibodies against oxidized LDL in patients with acute myocardial infarction. Free Radic Biol Med 18 (1995) 1087-1091
46. Tsimikas S., Lau H.K., Han K.R., et al. Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein. Circulation 109 (2004) 3164-3170